NCT04676529 is a Phase 1, PHASE2 clinical trial of PXS-5505 in Myelofibrosis, sponsored by Syntara.

Who is sponsoring NCT04676529?

NCT04676529 is sponsored by Syntara.

What drugs are being tested in NCT04676529?

Interventions in NCT04676529: PXS-5505.

What condition does NCT04676529 study?

NCT04676529 studies Myelofibrosis.

Is NCT04676529 still recruiting?

NCT04676529 is currently completed. Last updated 24 August 2025.

Last reviewed 2025-08-24 · How we verify

NCT04676529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Completed Phase 1, PHASE2 Last updated 24 August 2025

What this trial tests

Phase 1, PHASE2 trial testing PXS-5505 in Myelofibrosis in 43 participants. Completed in 9 July 2025.

Timeline

18 February 2021

Primary endpoint
9 July 2025

9 July 2025

Quick facts

Lead sponsor	Syntara
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	18 February 2021
Primary completion	9 July 2025
Estimated completion	9 July 2025
Sites	23 locations across Taiwan, United States, Australia, South Korea

Drugs / interventions tested

PXS-5505 — full drug profile →

Conditions studied

Myelofibrosis — all drugs for Myelofibrosis →

Sponsor

Syntara — full company profile →

Who can join

18 and older, any sex, with Myelofibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy.
Jiang Y, Zhang H, Wang J, Liu Y, et al · · 2022 · cited 342× · PMID 35331296 · DOI 10.1186/s13045-022-01252-0
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
Chitty JL, Yam M, Perryman L, Parker AL, et al · · 2023 · cited 99× · PMID 37640930 · DOI 10.1038/s43018-023-00614-y
Myelofibrosis.
Passamonti F, Mora B. · · 2023 · cited 82× · PMID 36416738 · DOI 10.1182/blood.2022017423
Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer.
Zhang M, Zhang B. · · 2025 · cited 69× · PMID 40211368 · DOI 10.1186/s40164-025-00647-2
Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy.
Xiong J, Xiao R, Zhao J, Zhao Q, et al · · 2024 · cited 39× · PMID 38246995 · DOI 10.1186/s12967-023-04810-3
Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis.
Yao Y, Findlay A, Stolp J, Rayner B, et al · · 2022 · cited 36× · PMID 35628342 · DOI 10.3390/ijms23105533
Lysyl Oxidase Family Proteins: Prospective Therapeutic Targets in Cancer.
Wang W, Wang X, Yao F, Huang C. · · 2022 · cited 32× · PMID 36293126 · DOI 10.3390/ijms232012270
Exploring Extracellular Matrix Crosslinking as a Therapeutic Approach to Fibrosis.
Lloyd SM, He Y. · · 2024 · cited 20× · PMID 38474402 · DOI 10.3390/cells13050438

Verify or expand the search:

Other recruiting trials for Myelofibrosis

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06781099 — Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis · NA · recruiting
NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
NCT07342712 — Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels · active not recruiting
NCT06533813 — Clinical Epidemiology in Contemporary Patients With Myelofibrosis. · recruiting

Other Syntara trials

Trials by the same sponsor.

NCT05904717 — Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder · Phase 2 · active not recruiting
NCT04183517 — A Two-part Pharmacokinetic Study of PXS-5382A in Healthy Adult Males · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04676529 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Syntara
Last refreshed: 24 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04676529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing